We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly’s Monoclonal Antibody Gets FDA Emergency Use Authorization
Eli Lilly’s Monoclonal Antibody Gets FDA Emergency Use Authorization
The FDA has issued an Emergency Use Authorization (EUA) for Eli Lilly’s monoclonal antibody treatment bamlanivimab (LY-CoV555), clearing the drug for use in high-risk patients with mild-to-moderate COVID-19 who don’t need hospitalization or oxygen.